title: Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - preliminary study.
abstract: BACKGROUND
  Fingolimod is a drug administered orally to adult patients treated for relapsing remitting course of multiple sclerosis (MS). Mode of action of fingolimod is based on intense S1P1 receptor stimulation and "arresting" lymphocytes in lymphatic organs. Objective of the research was to assess changes in the frequencies of basic lymphocyte subsets in patients treated for multiple sclerosis with the use of fingolimod.
  
  
  METHODS
  Study group comprised of 25 previously untreated adult patients with MS. Venous blood samples were collected from each patient before and one month, three months and six months after treatment initiation. Peripheral blood lymphocyte immunophenotype was assessed with a set of monoclonal antibodies bounded to appropriate fluorochromes and flow cytometer FACSC alibur. Statistical analysis of the results was conducted using Statistica 9.0 software.
  
  
  RESULTS
  Before fingolimod administration median of lymphocyte subsets percentage in each patient was in reference range. After 1 month of treatment we noticed significant changes in frequencies of following lymphocyte subsets: NK cells - 51.22% (p = 0.016), T CD4+ cells - 11.58% (p = 0.01), T CD4+:T CD8+ cells ratio - 0.61 (p = 0.005). After 3 and 6 months of treatment there was further increase of deviation from normal state.
  
  
  CONCLUSIONS
  The use of fingolimod is associated with profound changes in lymphocyte subsets distribution, which might bear a risk of the development of cellular immune deficiency symptoms.
authors.affiliation: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Poland.
authors.forename: Julia
authors.initials: J
authors.lastname: Rudnicka
authors.affiliation: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Poland.
authors.forename: Michał
authors.initials: M
authors.lastname: Czerwiec
authors.affiliation: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Poland.
authors.forename: Ewelina
authors.initials: E
authors.lastname: Grywalska
authors.affiliation: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Poland ; Department of Anesthesiology and Intensive Care, Medical University in Lublin, Poland.
authors.forename: Dorota
authors.initials: D
authors.lastname: Siwicka-Gieroba
authors.affiliation: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Poland.
authors.forename: Monika
authors.initials: M
authors.lastname: Walankiewicz
authors.affiliation: St. John's Cancer Center, Lublin, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Grafka
authors.affiliation: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Poland.
authors.forename: Michał
authors.initials: M
authors.lastname: Zgurski
authors.affiliation: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Poland ; St. John's Cancer Center, Lublin, Poland.
authors.forename: Agata
authors.initials: A
authors.lastname: Surdacka
authors.affiliation: Department of Neurology, Medical University in Lublin, Poland.
authors.forename: Halina
authors.initials: H
authors.lastname: Bartosik-Psujek
authors.affiliation: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Poland.
authors.forename: Jacek
authors.initials: J
authors.lastname: Roliński
keywords: MS; T CD4+:T CD8+ cells ratio; fingolimod; lymphocytes T; multiple sclerosis